You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Vertex’s Kalydeco scores another label extension in EU

Vertex has scored approval from the European Commission to extend the label for Kalydeco (ivacaftor) to include the treatment of infants with cystic fibrosis (CF) aged four months or older.